Full Length Research Paper
References
|
Ayouba A, Lien TTX, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-Huong N, Diop H, Kane CT, Valéa D, Rouet F, Joulia-Ekaza D, Toni TD, Nerrienet E, Ngole EM, Delaporte E, Costagliola D, Peeters M, Chaix ML (2009). Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam?: The ANRS 12134 study. AIDS Research and Human Retroviruses 25(11):1193?1196. |
|
|
Barth RE, van der Loeff MFS, Schuurman R, Hoepelman AIM, Wensing AMJ (2010). Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: A systematic review. The Lancet Infectious Diseases 10(3):155?166. |
|
|
Bijker R, Jiamsakul A, Kityo C, Kiertiburanakul S, Siwale M, Phanuphak P, Akanmu S, Chaiwarith R, Wi FW, Sim BL, Boender TS, Ditangco R, Rinke De Wit TF, Sohn AH, Hamers RL (2017). Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia?: A comparative analysis of two regional cohorts. Journal of the International AIDS Society 20(1):21218. |
|
|
Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JCJ, Rinke de Wit TF, Sigaloff KCE (2016). Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. The Journal of Antimicrobial Chemotherapy 71(10):2918?2927. |
|
|
Boullé C, Guichet E, Kouanfack C, Aghokeng A, Onambany B, Ikaka C M, Ngock E, Tsoumsta L, Msellati P, Mpoudi-Ngolé E, Peeters M, Delaporte E, Laurent C (2016). Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets. Open Forum Infectious Diseases 3(4). |
|
|
De Beaudrap P, Thiam M, Diouf A, Toure-Kane C, Ngom-Guèye NF, Vidal N, Mboup S, Ndoye I, Sow, PS, Delaporte E, ANRS 1215 Study Group. (2013). Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal?: Results from the ANRS 1215 cohort. Journal of Acquired Immune Deficiency Syndromes 62(4):381?387. |
|
|
Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D. (2006). Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. Journal of Medical Virology 78(2):153-160. |
|
|
Diouara AAM, Diop-Ndiaye H, Kebe-Fall K, Tchiakpè E, Ndiaye O, Ayouba A, Peeters M, Mboup S, Kane CT (2014). Dried blood spots for HIV-1 drug resistance genotyping in decentralized settings in Senegal. Journal of Medical Virology 86(1):45-51. |
|
|
Diouara AAM, Ndiaye HD, Guindo I, Bangoura N, Cissé M, Edmond T, Bougoudogo F, Mboup S, Peeters M, Ayouba A, Kane NCT (2014). Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry. Journal of the International AIDS Society 17, 19315. |
|
|
Eholie SP, Moh R, Benalycherif A, Gabillard D, Ello F, Messou E, Zoungrana J, Diallo I, Diallo M, Bado G, Cisse M, Maiga AI, Anzian A, Toni T, Congo-Ouedraogo M, Toure-Kane C, Seydi M, Minta DK, Sawadogo A, Thilao ANRS 12269 Study Group (2019). Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing?: A prospective cohort study. The Lancet HIV 6(11):e750-e759. |
|
|
Feder AF, Rhee SY, Holmes SP, Shafer RW, Petrov DA, Pennings PS (2016). More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. ELife 5:e10670. |
|
|
Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, Dabis F, Davies MA, Hoffmann CJ, Oyaro P, Parkes-Ratanshi R, Reynolds SJ, Sikazwe I, Wools-Kaloustian K, Zannou DM, Wandeler G, Egger M (2015). IeDEA southern Africa, east Africa, and west Africa. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa?: Collaborative analysis. The Lancet HIV 2(7):e271-278. |
|
|
Hamers RL, Sigaloff KCE, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R (2012). PharmAccess African Studies to Evaluate Resistance (PASER). Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries?: Implications for second-line ART strategies. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 54(11):1660-1669. |
|
|
Hammond R, Harry TC (2008). Efficacy of antiretroviral therapy in Africa?: Effect on immunological and virological outcome measures -- a meta-analysis. International Journal of STD & AIDS 19(5):291-296. |
|
|
INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD (2015). Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England Journal of Medicine 373(9):795?807. |
|
|
Ivers LC, Kendrick D, Doucette K. (2005). Efficacy of antiretroviral therapy programs in resource-poor settings?: A meta-analysis of the published literature. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 41(2):217-224. |
|
|
Konou AA, Dagnra AY, Vidal N, Salou M, Adam Z, Singo-Tokofai A, Delaporte E, Prince-David M, Peeters M (2015). Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo. AIDS (London, England) 29(18):2527?2530. |
|
|
Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D (2015). Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia?: A cross-sectional study. The Journal of Antimicrobial Chemotherapy 70(6):1881-1884. |
|
|
Messou E, Chaix ML, Gabillard D, Minga A, Losina E, Yapo V, Kouakou M, Danel C, Sloan C, Rouzioux C, Freedberg KA, Anglaret X (2011). Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. Journal of Acquired Immune Deficiency Syndromes 56(4):356-364. |
|
|
Messou E, Chaix ML, Gabillard D, Yapo V, Toni T, Minga A, Kouakou MG, Ouattara E, Rouzioux C, Danel C, Eholie SP, Anglaret X (2013). Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment?: The VOLTART cohort study in Côte d'Ivoire, West Africa. Journal of Acquired Immune Deficiency Syndromes 64(2):211-219. |
|
|
Médecins sans frontières (MSF) (2016). Rapport Le Prix de l'oubli-Des millions de personnes en Afrique occidentale et centrale restent en marge de la lutte mondiale contre le VIH. Médecins sans frontières. |
|
|
Namakoola I, Kasamba I, Mayanja BN, Kazooba P, Lutaakome J, Lyagoba F, Kapaata AA, Kaleebu P, Munderi P (2016). CoLTART study team. From antiretroviral therapy access to provision of third line regimens?: Evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults. BMC Research Notes 9(1):515. |
|
|
Pasquier C, Millot N, Njouom R, Sandres K, Cazabat M, Puel J, Izopet J (2001). HIV-1 subtyping using phylogenetic analysis of pol gene sequences. Journal of Virological Methods, 94(1-2):45-54. |
|
|
Pham MD, Romero L, Parnell B, Anderson DA, Crowe SM, Luchters S (2017). Feasibility of antiretroviral treatment monitoring in the era of decentralized HIV care?: A systematic review. AIDS Research and Therapy 14(1):3. |
|
|
Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Ekouevi DK, Msellati P, Ferradini L, Rukobo S, Maréchal V, Schvachsa N, Wakrim L, Rafalimanana C, Rakotoambinina B, Viard JP, Seigneurin JM, Rouzioux C (2007). Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification?: Usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test. Journal of Acquired Immune Deficiency Syndromes 45(4):380-388. |
|
|
Sigaloff KCE, de Wit TFR (2015). ART in sub-Saharan Africa: The value of viral load monitoring. The Lancet HIV 2(7):e261-262. |
|
|
Steegen K, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, Variava E, MacLeod W, Sanne I, Stevens WS, Carmona S (2017). HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment?: Results from a national survey in South Africa. The Journal of Antimicrobial Chemotherapy 72(1):210-219. |
|
|
Taieb F, Madec Y, Cournil A, Delaporte E (2017). Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa?: Comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis. PloS One 12(4):e0174767. |
|
|
TEMPRANO ANRS 12136 Study Group, Danel, C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, Ouattara E, Anzian A, Ntakpé JB, Minga A, Kouame GM, Bouhoussou F, Emieme A, Kouamé A, Inwoley A, Toni T, Ahiboh H, Kabran M, Anglaret X (2015). A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. The New England Journal of Medicine 373(9):808-822. |
|
|
Toni T. d'Aquin, Masquelier B, Minga A, Anglaret X, Danel C, Coulibaly A, Chenal H, Dabis F, Salamon R, Fleury HJ, Primo-CI ANRS 1220 Study Group (2007). HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire?: A 4-year survey, 2002-2006. AIDS Research and Human Retroviruses 23(9):1155-1160. |
|
|
UNAIDS (n. d.). UNAIDS (2020). Country factsheets, Côte d'Ivoire. Consulté 10 décembre 2021, à l'adresse. |
|
|
Villabona-Arenas CJ, Vidal N, Guichet E, Serrano L, Delaporte E, Gascuel O, Peeters M (2016). In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa. AIDS (London, England) 30(17):2577-2589. |
|
|
World Health Organization (WHO) (2010). Antiretroviral Therapy for HIV Infection in Adults and Adolescents?: Recommendations for a Public Health Approach: 2010 Revision. World Health Organization. |
|
|
World Health Organization (WHO) (2019). Policy brief?: Update of recommendations on first- and second-line antiretroviral regimens (WHO/CDS/HIV/19.15). World Health Organization. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
